Suppr超能文献

胃原发性癌及其转移灶中 HER2 不一致性的荟萃分析。

HER2 discordance between paired primary gastric cancer and metastasis: a meta-analysis.

机构信息

1 Department of Gastrointestinal Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital & Institute, Beijing 100142, China ; 2 Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences & School of Basic Medicine Peking Union Medical College, Beijing 100730, China.

出版信息

Chin J Cancer Res. 2015 Apr;27(2):163-71. doi: 10.3978/j.issn.1000-9604.2014.12.09.

Abstract

BACKGROUND

A number of studies have examined human epidermal growth factor receptor 2 (HER2) status in primary gastric cancer (GC) and associated metastasis, some showed their great concordance in HER2 expression, but others demonstrated notable discordance. There is still little consensus on HER2 discordance, therefore, a systematic review and meta-analysis was conducted to assess the status on HER2 discordance between primary GC and its paired metastasis.

METHODS

PubMed, EMBASE, ASCO and The Cochrane Library were searched for studies that explored the concordance between primary tumor and metastasis in patients with GC up to 10 March, 2014. Data of discordance of HER2 between primary GC and corresponding metastasis were extracted from the publications and random-effects models were used to estimate pooled discordance proportions.

RESULTS

Eighteen articles including 1,867 patients were included for the meta-analysis in accordance with the selection criteria. Pooled discordance proportions were 7% [95% confidence interval (CI): 5-10%] for HER2 status. Pooled proportions of tumors shifting from positive to negative and from negative to positive were 17% (95% CI: 7-29%) and 4% (95% CI: 2-6%) respectively. No publication bias was found in the meta-analysis.

CONCLUSIONS

The discordance of HER2 status is not rare in primary and metastatic GC through our meta-analysis. Prospective studies are needed to testify the clinical significance of the discordance of HER2 status.

摘要

背景

许多研究已经检查了人表皮生长因子受体 2(HER2)在原发性胃癌(GC)及其相关转移中的状态,一些研究表明其在 HER2 表达方面具有很好的一致性,但其他研究则显示出明显的不一致性。HER2 不一致性仍存在较小的共识,因此,进行了系统评价和荟萃分析,以评估原发性 GC 与其配对转移之间 HER2 不一致性的状况。

方法

检索了 PubMed、EMBASE、ASCO 和 Cochrane 图书馆,以查找截至 2014 年 3 月 10 日探讨 GC 患者中肿瘤与转移之间一致性的研究。从出版物中提取了原发性 GC 和相应转移中 HER2 不一致性的数据,并使用随机效应模型估计了汇总的不一致性比例。

结果

根据选择标准,有 18 篇文章包括 1867 例患者被纳入荟萃分析。HER2 状态的汇总不一致性比例为 7%(95%置信区间:5-10%)。肿瘤从阳性转为阴性和从阴性转为阳性的汇总比例分别为 17%(95%置信区间:7-29%)和 4%(95%置信区间:2-6%)。荟萃分析中未发现发表偏倚。

结论

通过荟萃分析,原发性和转移性 GC 中 HER2 状态的不一致性并不罕见。需要前瞻性研究来验证 HER2 状态不一致性的临床意义。

相似文献

1
HER2 discordance between paired primary gastric cancer and metastasis: a meta-analysis.
Chin J Cancer Res. 2015 Apr;27(2):163-71. doi: 10.3978/j.issn.1000-9604.2014.12.09.
2
HER2 discordance between primary breast cancer and its paired metastasis: tumor biology or test artefact? Insights through meta-analysis.
Breast Cancer Res Treat. 2011 Oct;129(3):659-74. doi: 10.1007/s10549-011-1632-x. Epub 2011 Jun 23.
4
Discordances in HER2 status between primary gastric cancer and corresponding metastatic sites.
Jpn J Clin Oncol. 2015 May;45(5):416-21. doi: 10.1093/jjco/hyv020. Epub 2015 Mar 2.
6
Systematic review and meta-analysis of breast cancer brain metastasis and primary tumor receptor expression discordance.
Neurooncol Adv. 2021 Jan 16;3(1):vdab010. doi: 10.1093/noajnl/vdab010. eCollection 2021 Jan-Dec.

引用本文的文献

1
Evolution of HER2-low expression from primary to paired metastatic gastric cancer lesions.
NPJ Precis Oncol. 2025 Apr 15;9(1):108. doi: 10.1038/s41698-025-00881-1.
4
Molecular classification and intratumoral heterogeneity of gastric adenocarcinoma.
Pathol Int. 2024 Jun;74(6):301-316. doi: 10.1111/pin.13427. Epub 2024 Apr 23.
5
Liquid biopsy based HER2 amplification status in gastric cancer patients indicates clinical response.
Heliyon. 2023 Nov 2;9(11):e21339. doi: 10.1016/j.heliyon.2023.e21339. eCollection 2023 Nov.
6
Human Epidermal Growth Factor Receptor-2 Gastric Adenocarcinoma: Expanding Therapy of a Recognized Target.
Cancers (Basel). 2023 Oct 27;15(21):5180. doi: 10.3390/cancers15215180.
7
Ado-tratuzumab emtansine beyond breast cancer: therapeutic role of targeting other HER2-positive cancers.
Front Mol Biosci. 2023 May 11;10:1165781. doi: 10.3389/fmolb.2023.1165781. eCollection 2023.
8
A Standardized Pathology Report for Gastric Cancer: 2nd Edition.
J Gastric Cancer. 2023 Jan;23(1):107-145. doi: 10.5230/jgc.2023.23.e7.
9
A standardized pathology report for gastric cancer: 2nd edition.
J Pathol Transl Med. 2023 Jan;57(1):1-27. doi: 10.4132/jptm.2022.12.23. Epub 2023 Jan 15.
10
Current Laboratory Testing Practices for Assessment of ERBB2/HER2 in Endometrial Serous Carcinoma and Colorectal Carcinoma.
Arch Pathol Lab Med. 2023 Oct 1;147(10):1148-1157. doi: 10.5858/arpa.2022-0229-CP.

本文引用的文献

4
HER2 testing: current status and future directions.
Cancer Treat Rev. 2014 Mar;40(2):276-84. doi: 10.1016/j.ctrv.2013.09.001. Epub 2013 Sep 11.
5
Human epidermal growth factor receptor-2 expression in primary and metastatic gastric cancer.
Int J Clin Oncol. 2014 Apr;19(2):303-11. doi: 10.1007/s10147-013-0542-9. Epub 2013 May 10.
7
HER2-positive gastric cancer.
Gastric Cancer. 2014 Jan;17(1):1-12. doi: 10.1007/s10120-013-0252-z. Epub 2013 Apr 7.
8
HER2 in gastric cancer: a digital image analysis in pre-neoplastic, primary and metastatic lesions.
Mod Pathol. 2013 Jun;26(6):816-24. doi: 10.1038/modpathol.2012.228. Epub 2013 Jan 25.
9
Cancer statistics, 2013.
CA Cancer J Clin. 2013 Jan;63(1):11-30. doi: 10.3322/caac.21166. Epub 2013 Jan 17.
10
Heterogeneity of ERBB2 in gastric carcinomas: a study of tissue microarray and matched primary and metastatic carcinomas.
Mod Pathol. 2013 May;26(5):677-84. doi: 10.1038/modpathol.2012.205. Epub 2012 Dec 14.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验